Lineage Cell Therapeutics, Inc.LCTXNYSE
Loading
LCTX Revenue Growth (YoY Quarterly)•+130.40%
Stock Alarm Pro
Growth Metrics
Latest: Q4 2025vs Q3 2025
Revenue GrowthGross Profit GrowthEBITDA GrowthOperating Income GrowthNet Income GrowthEPS GrowthEPS Diluted GrowthWeighted Average Shares GrowthWeighted Average Shares Diluted GrowthDividends per Share Growth
+130.40%
+133.0pp
+115.29%
+117.0pp
+0.00%
+0.0pp
+0.00%
+0.0pp
+0.00%
+0.0pp
+0.00%
+0.0pp
+0.00%
+0.0pp
+14.95%
-6.2pp
+14.95%
-6.2pp
+0.00%
+0.0pp
| Metric | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 |
|---|---|---|---|---|---|
| Revenue Growth | +37.36% | +4.02% | +96.38% | -2.59% | +130.40% |
| Gross Profit Growth | +63.79% | +25.19% | +99.85% | -1.74% | +115.29% |
| EBITDA Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Operating Income Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Net Income Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| EPS Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| EPS Diluted Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Weighted Average Shares Growth | +15.94% | +23.59% | +20.94% | +21.19% | +14.95% |
| Weighted Average Shares Diluted Growth | +15.94% | +23.59% | +20.94% | +21.19% | +14.95% |
| Dividends per Share Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Operating Cash Flow Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Free Cash Flow Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Receivables Growth | -14.36% | +176.62% | +8.94% | -68.64% | +144.83% |
| Inventory Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Asset Growth | +12.08% | +3.01% | -11.68% | -7.20% | -0.56% |
| Book Value per Share Growth | +6.60% | -11.68% | -41.43% | -72.52% | -50.55% |
| Debt Growth | -14.84% | -31.04% | -27.01% | -4.69% | -3.78% |
| R&D Expense Growth | -11.64% | +4.22% | +8.30% | +3.15% | +140.67% |
| SG&A Expenses Growth | +6.18% | +0.27% | +4.52% | -4.97% | +10.25% |
1 / 4